Who are ORAL VORICONAZOLE and IV Amphotericin B's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oral-voriconazole-and-iv-amphotericin-b.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

ORAL VORICONAZOLE and IV Amphotericin B — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ORAL VORICONAZOLE and IV Amphotericin B (ORAL VORICONAZOLE and IV Amphotericin B) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifungal agents (triazole and polyene). Area: Infectious Disease.

phase 3 Antifungal agents (triazole and polyene) Fungal cytochrome P450 lanosterol 14α-demethylase (voriconazole); ergosterol (amphotericin B) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

ORAL VORICONAZOLE and IV Amphotericin B (ORAL VORICONAZOLE and IV Amphotericin B) — All India Institute of Medical Sciences. Voriconazole and amphotericin B are antifungal agents that disrupt fungal cell membrane integrity, while voriconazole inhibits ergosterol synthesis and amphotericin B binds directly to ergosterol causing cell lysis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ORAL VORICONAZOLE and IV Amphotericin B TARGET	ORAL VORICONAZOLE and IV Amphotericin B	All India Institute of Medical Sciences	phase 3	Antifungal agents (triazole and polyene)	Fungal cytochrome P450 lanosterol 14α-demethylase (voriconazole); ergosterol (amphotericin B)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifungal agents (triazole and polyene) class)

All India Institute of Medical Sciences · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ORAL VORICONAZOLE and IV Amphotericin B — Competitive Intelligence Brief. https://druglandscape.com/ci/oral-voriconazole-and-iv-amphotericin-b. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab